CompletedPhase 2NCT01322269
A Study of HQK-1001 in Patients With Sickle Cell Disease
Studying Sickle cell anemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- HemaQuest Pharmaceuticals Inc.
- Principal Investigator
- Richard Ghalie, MD, MBAHemaQuest Pharmaceuticals Inc.
- Intervention
- HQK-1001(drug)
- Enrollment
- 52 enrolled
- Eligibility
- 12-60 years · All sexes
- Timeline
- 2011
Study locations (16)
- Children's Hospital and Research Center - Oakland, Oakland, California, United States
- University of Miami Miller School of Medicine - Dept of Pediatrics, Miami, Florida, United States
- Georgia Health Sciences University - Adult SIckle Cell Center, Augusta, Georgia, United States
- University of Illinois at Chicago - Dept of Pediatrics, Chicago, Illinois, United States
- LSU Health Sciences Center - Feist Weiller Cancer Center, Shreveport, Louisiana, United States
- Tufts Medical Center, Boston, Massachusetts, United States
- University of North Carolina at Chapel Hill - Comprehensive Sickle Cell Program, Chapel Hill, North Carolina, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- Univerisity of Texas Southwestern Medical Center at Dallas - Pediatric Hematology Oncology, Dallas, Texas, United States
- The Hospital for Sick Children, Toronto, Ontario, Canada
- University Health Network Toronto General Hospital, Toronto, Ontario, Canada
- Abu El Reesh Pediatric University Hospital, Cairo, Egypt
- University of the West Indies - Sickle Cell Unit, Mona, Kingston, Jamaica
- American University of Beirut Medical Center, Beirut, Lebanon
- Rafik Hariri University Hospital, Beirut, Lebanon
- +1 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01322269 on ClinicalTrials.govOther trials for Sickle cell anemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07369024Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young AdultsMohsen Saidinejad
- RECRUITINGNCT07373639A Long-term Follow-up Study in Patients Who Received BEAM-101Beam Therapeutics Inc.
- RECRUITINGNANCT07402811Mindfulness-Based Intervention for Pain and Sleep in Adolescents and Young Adults With Sickle Cell DiseaseUniversity of Illinois at Chicago
- RECRUITINGPHASE1NCT06647979Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-HemoglobinopathiesDaniel Bauer
- RECRUITINGNANCT06555939Promoting Resilience Among Adolescents and Young Adults With Sickle Cell DiseaseBoston Children's Hospital
- RECRUITINGPHASE3NCT06975865The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell DiseaseSanofi
- RECRUITINGNCT06944067Study to Understand the Genetic Risk of Developing an Immune Response After Blood Transfusions Among Individuals With Sickle Cell DiseaseNational Human Genome Research Institute (NHGRI)
- RECRUITINGNCT06923111PASS of Xromi Comparing Safety and Effectiveness in Children Under 2 Years With Sickle Cell Disease [PRECISE PASS]Nova Laboratories Limited